首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1526806

抗TIGIT抗體市場:臨床試驗與市場機會預測:2028年

Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028

出版日期: 2024年08月01日 | 出版商:

KuicK Research | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

抗TIGIT抗體已成為癌症免疫治療中一種有前途的方法，為各種癌症類型，特別是實體瘤患者帶來新的希望。 TIGIT（具有 Ig 和 ITIM 結構域的 T 細胞免疫受體）是 T 細胞和自然殺手 (NK) 細胞上表達的抑制性受體，在調節免疫反應中發揮重要作用。標靶 TIGIT 可以增強免疫系統識別和消除癌細胞的能力，從而可能徹底改變癌症治療策略。

TIGIT 作為癌症免疫治療標靶的治療潛力在於其作為免疫檢查點分子的功能。當 TIGIT 與 CD155 和 CD112 等配體相互作用時，它可能會抑制 T 細胞和 NK 細胞的激活，從而使癌細胞逃避免疫監視。透過使用抗 TIGIT 治療方法阻斷這種相互作用，研究人員希望重新激活針對腫瘤的免疫反應並改善癌症患者的臨床結果。

在針對 TIGIT 的各種方法中，單株抗體已成為使用最廣泛和最有前途的藥物。這些抗體被設計為特異性結合 TIGIT，抑制其與其配體的相互作用並釋放免疫系統中的 "斷開" 。抗體的高特異性和相對低的毒性使其成為臨床開發的有吸引力的候選者。

抗 TIGIT 抗體的開發進展迅速，目前有 50 多個候選抗體處於臨床開發階段。這條強大的產品線支持了這種方法在癌症治療中的巨大興趣和潛力。其中，超過5種抗TIGIT抗體已進入3期臨床試驗，這是監管部門批准前臨床開發的最高級階段。其中包括分別由醫藥標記物領導者默克基因泰克和百濟神州開發的vivostlimab、tiragolumab和ocipelilimab。

本報告提供全球抗TIGIT抗體市場相關調查，提供市場概要，以及抗TIGIT抗體的臨床實驗平台，各適應症，各國趨勢，及市場參與市場企業的競爭趨勢等資訊。

Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies
First Anti TIGIT Antibody To Get Approval Within Next 5 Years
Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase
Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials
Anti TIGIT Antibodies Market Trends by Indication & Country
Global Anti TIGIT Antibodies Market Dynamics

Anti TIGIT antibodies have emerged a promising approach in cancer immunotherapy, offering new hope for patients with various types of cancers, particularly solid cancers. TIGIT (T cell immunoreceptor with Ig and ITIM domains) is an inhibitory receptor expressed on T cells and natural killer (NK) cells, playing a crucial role in modulating immune responses. By targeting TIGIT, researchers aim to enhance the immune system's ability to recognize and eliminate cancer cells, potentially revolutionizing cancer treatment strategies.

The therapeutic potential of TIGIT as a target for cancer immunotherapy lies in its function as an immune checkpoint molecule. When TIGIT interacts with its ligands, such as CD155 and CD112, it suppresses T cell sand NK cell activation, potentially allowing cancer cells to evade immune surveillance. By blocking this interaction with anti-TIGIT therapeutic approaches, researchers hope to reinvigorate the immune response against tumors, leading to improved clinical outcome for cancer patients.

Among the various approaches for targeting TIGIT, monoclonal antibodies have emerged as the most widely used and promising agents. These antibodies are designed to specifically bind to TIGIT, preventing its interaction with its ligands and thus releasing the "breaks" on the immune system. Their high specificity and relatively low toxicity of antibodies make them attractive candidates for clinical development.

The field of anti-TIGIT antibody development has seen rapid progress, with over 50 candidates currently in clinical development. This robust pipeline underscores the significant interest and potential of this approach in cancer treatment. Among these, more than five anti TIGIT antibodies have advanced to phase 3 clinical trials, representing the most advanced stage of clinical development before potential regulatory approval. These include Vibostolimab, Tiragolumab and Ociperlimab, developed by the pharmaceutical marker leaders, Merck Genentech and BeiGene, respectively.

These phase 3 clinical trials are assessing the safety and efficacy of these anti-TIGIT antibodies in various cancer types, with a particular focus on non-small cell lung cancer (NSCLC). The emphasis on NSCLC is not surprising, given its high prevalence and the need for more effective treatment options. NSCLC represents a significant portion of lung cancer cases and has shown promising responses to immunotherapy approaches in the past.

Several key factors are driving the market potential of anti-TIGIT antibodies. Firstly, there remains a substantial unmet medical need in cancer treatment, especially for patients who do not respond to or develop resistance to existing immunotherapies. Anti-TIGIT antibodies offer a novel mechanism of action that could address these challenges. Moreover, these antibodies show promising results in combination with established therapies like PD-1/L1 inhibitors, potentially expanding the market for both drug classes and improving treatment outcomes. This becomes visible in Merck's vision of developing a coformulation of its anti-TIGIT antibody Vibostolimab with its blockbuster anti-PD-1 antibody pembrolizumab for the treatment of various solid tumors.

The broad applicability of anti-TIGIT antibodies across various cancer forms presents another significant market opportunity. While a majority of clinical trials currently focus on NSCLC, many other ongoing clinical trials are exploring their efficacy in other solid cancers tumors and hematological malignancies, which could lead to multiple approved indications, consequently increasing the anti-TIGIT antibody market size.

As evident from the examples above, the competitive landscape for the anti-TIGIT antibody market is dynamic, with major pharmaceutical companies and biotechnology firms vying for market share. While Vibostolimab leverages the company's strong position in the immuno-oncology market, another, Domvanalimab, being developed by Gilead Sciences and Arcus Biosciences, benefits from a partnership between a major pharmaceutical company and a competent biopharmaceutical company.

In conclusion, anti-TIGIT antibodies not only represent a significant advancement in cancer immunotherapy, but also present many opportunities for drug development and market expansion. With its potential to address unmet medical needs, broad applicability and alignment with personalized medicine, this emerging class of drugs is poised to capture a substantial portion of cancer immunotherapy market.

1. Introduction to Anti TIGIT Antibody

1.1 Overview
1.2 Mechanism of Anti TIGIT Antibodies
1.3 Clinical Approaches to Target TIGIT

2. Global Anti TIGIT Antibodies Clinical Trials Overview

2.1 By Company
2.2 By Country
2.3 By Indication
2.4 By Patient Segment
2.5 By Phase

3. Global Anti TIGIT Antibodies Clinical Pipeline By Company, Indication and Phase

3.1 Research
3.2 Preclinical
3.3 Phase I
3.4 Phase I/II
3.5 Phase II
3.6 Phase III

4. Global Anti TIGIT Antibodies Market Outlook

4.1 Current Clinical & Market Trends
4.2 Future Market Outlook

5. Anti TIGIT Antibodies Market Trends by Indication

5.1 Cancer
5.2 Autoimmune & Inflammatory Disorders
5.3 Microbial Infections

6. Anti TIGIT Antibodies Market By Country

6.1 US
6.2 China
6.3 South Korea
6.4 Australia
6.5 UK

7. Combinations Approaches for TIGIT Therapy

8. TIGIT Co Inhibition with PD1 or PDL1

9. Global Anti TIGIT Antibodies Market Dynamics

9.1 Market Drivers
9.2 Commercialization Challenges

10. Competitive Landscape

10.1 Akeso Biopharma
10.2 BeiGene
10.3 Bio-Thera Solutions
10.4 Biotheus
10.5 Compugen
10.6 FutureGen Biopharmaceutical
10.7 Merck Sharp & Dohme
10.8 Nanjing Sanhome Pharmaceutical
10.9 OriCell Therapeutics
10.10 Phio Pharmaceuticals
10.11 Roche
10.12 Shanghai Henlius Biotech
10.13 Shanghai Junshi Biosciences
10.14 Simcere Pharmaceutical Group
10.15 Tasrif Pharmaceutical

簡介目錄圖表

List of Figures

Figure 1-1: TIGIT/DNAX Accessory Molecule-1 Pathway
Figure 1-2: TIGIT Inhibitor - Proposed Mechanism of Action

Figure 1*3: TIGIT Inhibitor - Mechanism of Action

Figure 1-4: Binding Efficacy of Monoclonal Antibody
Figure 1-5: Binding Efficacy of Bispecific Antibodies
Figure 1-6: Advantages of Small Molecule Drugs over Therapeutic Antibodies
Figure 2-1: Global - Anti TIGIT Antibodies Clinical Trials by Company (Number of Drugs), 2024 -2028
Figure 2-2: Global - Anti TIGIT Antibodies Clinical Trials by Country (Number of Drugs), 2024 - 2028
Figure 2-3: Global - Anti TIGIT Antibodies Clinical Trials by Indication (Number of Drugs), 2024 - 2028
Figure 2-4: Global - Anti TIGIT Antibodies Clinical Trials by Patient Segment (Number of Drugs), 2024 - 2028
Figure 2-5: Global - Anti TIGIT Antibodies Clinical Trials by Phase (Number of Drugs), 2024 -2028

Figure 4 1: Global TIGIT Therapy Fundamental Companies

Figure 4 2: Future TIGIT Market

Figure 5-1: Anti-LAG-3 (BMS-986016) & Anti-TIGIT (BMS-986207) Phase I/II (NCT04150965) Study - Initiation & Completion Year
Figure 5-2: Compugen TIGIT Antibody Cancer Pipeline
Figure 5-3: Keio University School of Medicine Research Study
Figure 5-4: University of Zurich Investigation for TIGIT Antibody to Cure Viral Infection
Figure 5-5: Combination TIGIT Therapy for Viral Infections
Figure 6-1: PD-1 Inhibitor Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) Phase II (NCT05130177) Study - Initiation & Completion Year
Figure 6-2: iTeos Therapeutics & GSK Triumph Enrolment Milestone
Figure 6-3: Bristol Myers Squibb & Agenus Preclinical Candidates, BMS-986442
Figure 6-4: Clinical TIGIT Therapy Pipeline in China
Figure 6-5: JS006 Monotherapy and in Combination With Toripalimab Phase I (NCT05061628) Study - Initiation & Completion Year
Figure 6-6: Chinese Companies TIGIT Candidates Insights
Figure 6-7: Zimberelimab with Domvanalimab Phase II (NCT04262856) Study - Initiation & Completion Year
Figure 6-8: Aspects Influencing South Korea TIGIT Market
Figure 6-9: HLX301 Phase I/II (NCT05102214) Study - Initiation & Completion Year
Figure 6-10: AZD8205 Monotherapy or in Combination with Anticancer Drugs Phase I/II (NCT05123482) Study - Initiation & Completion Year
Figure 6-11: Key Players in UK TIGIT Market
Figure 7-1: TIGIT Therapy Combinations
Figure 9-1: Global - Cancer Incidences & Deaths (Million), 2020 & 2025
Figure 9-2: TIGIT Inhibitor Market Drivers
Figure 9-3: Stages of Drug Development

List of Tables

Table 1-1: Anti-TIGIT Monoclonal Antibodies in Development
Table 5-1: Ongoing Cancers Clinical Trials for TIGIT Therapy
Table 6-1: Ongoing US Clinical Trials for TIGIT Therapy
Table 6-2: Ongoing China Clinical Trials for TIGIT Therapy
Table 7-1: Ongoing Preclinical & Clinical Trials for Combination of TIGIT inhibitors

02-2729-4219

+886-2-2729-4219